Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 64Leukemia 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Myelodysplastic Syndromes 56Leukemia, Lymphocytic, Chronic, B-Cell 54Multiple Myeloma 49Lymphoma, Non-Hodgkin 49Hodgkin Disease 47Lymphoma, Mantle-Cell 41Lymphoma, Large B-Cell, Diffuse 39Lymphoma, Follicular 39Leukemia, Myeloid, Chronic-Phase 39Lymphoma, B-Cell, Marginal Zone 35Lymphoma 35Burkitt Lymphoma 35Lymphoma, Large-Cell, Immunoblastic 34Myeloproliferative Disorders 33Congenital Abnormalities 32Leukemia, Myeloid, Accelerated Phase 31Anemia, Refractory, with Excess of Blasts 30Leukemia, Myelomonocytic, Chronic 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24Dendritic Cell Sarcoma, Interdigitating 23Blast Crisis 23Waldenstrom Macroglobulinemia 21Recurrence 21Lymphoma, T-Cell, Cutaneous 20Anemia, Refractory 19Sezary Syndrome 18Graft vs Host Disease 18

Interventions

Tacrolimus 1Phlebotomy 1Cyclosporins 1Cyclosporine 1Blood Specimen Collection 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thymic aplasia × Cyclosporine × Clear all
NCT02274662 2025-01-16

Expanded Access Protocol Thymus Transplantation

Sumitomo Pharma Switzerland GmbH

Phase 4 Completed
11 enrolled 10 charts

Thymic aplasia, Immunologic Deficiency Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡